About UsAbout ALSCanada’s ALS StoriesNewsInterviewsTake ActionContactDonate Now
Donate NowMedical professionnalsPatient & Families
alt text

Early ALS Detection with AI

Published September 29, 2023

Canadian-Developed AI Technology Aims to Support Early Detection of ALS

MNd-5 algorithm screens electronic medical records to assist physicians in identifying individuals for which follow-up investigations for ALS may be appropriate

An initiative known as the “Process for Progress in ALS: An EMR-Based Practice Initiative”, is a collaboration of Mitsubishi Tanabe Pharma Canada (MTP-CA) and a trio of ALS experts. The scientists are Angela Genge, MD, executive director of the ALS Centre of Excellence at The Neuro, in Montreal; Amer A. Ghavanini, PhD, division head of neurology at Trillium Health Partners in Mississauga, Canada; and Amanda Fiander, a neurologist at Maritime Neurology, in Nova Scotia.

An AI program is used to analyze de-identified electronic medical records (EMRs) and detect individuals who should be tested for ALS or referred to a specialty centre. It employs a clinical algorithm — called MNd-5 and using real-world patient data — that screens EMRs and related patient EMGs to help physicians spot patients for whom investigations for the neurodegenerative disorder may be appropriate.

Read more about this initiative here:

https://www.alsprogress.ca/


Original Release:

https://www.newswire.ca/news-releases/canadian-developed-ai-technology-aims-to-support-early-detection-of-als-830241196.html

Join our fight to #EndALS!

Sign up as to receive periodic email updates and join our circle of supporters!

Subscribe to our newsletter
Privacy PolicyAbout ALSResearchStoriesNewsTake Action

Hope is on the Horizon

Although an ALS diagnosis has been treated as a death sentence, new treatments that can stop and even reverse progression are in development. 

Join the fight on social